Education and Training

Radiation Therapy Residency

Medical Students

Medical Physics Residency

Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

This study will assess the safety and efficacy of Posoleucel for the treatment of adenovirus (AdV) infection in pediatric and adult allo-HCT recipients receiving standard of care (SoC).

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • drug: Posoleucel
  • drug: Placebo

Eligibility


Inclusion Criteria:

   - Undergone allogeneic cell transplantation ≥21 days prior to dosing

   - Meet one of the below criteria:

      1. AdV viremia DNA ≥10,000 copies/mL, OR

      2. AdV viremia DNA results of ≥1,000 copies/mL, AND

         1. has absolute lymphocyte count <180/mm3, OR

         2. has received T cell depletion OR

         3. had a cord blood transplant.

Exclusion Criteria:

   - Grade 3 or higher acute GVHD

   - Ongoing therapy with high-dose systemic corticosteroids

   - Uncontrolled viral (other than AdV), bacterial, or fungal infection(s)

   - Pregnant or lactating female unwilling to discontinue nursing prior to randomization

   - History of severe prior reactions to blood product transfusions

NOTE: Other protocol-defined inclusion/exclusion criterion may apply.

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maninder Singh
msclinic@stanford.edu
I'm interested